Find Academic Supervisors

Allison Ross Eckard, MD is Professor in the Departments of Pediatrics and Medicine at the Medical University of South Carolina (MUSC) College of Medicine, serving as Division Chief for Pediatric Infectious Diseases and Director of MUSC's Ryan White Pediatric HIV Clinic and HIV Transition Clinic. She maintains an adjunct faculty position at Emory University and holds board certification in Pediatrics and Pediatric Infectious Diseases. Her primary research focuses on metabolic, cardiovascular, and nutritional complications of chronic HIV and antiretroviral therapy across age groups, with emphasis on inflammation's role in comorbidities like cardiovascular disease and bone disorders. Current investigations include NIH R01-funded research on interventions for weight gain and abdominal fat in HIV, vitamin D supplementation, and statin therapy. She has published nearly 60 peer-reviewed papers on HIV pathogenesis and treatment optimization. Dr. Eckard co-chairs the DHHS panel for Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children and serves on the DHHS panel for Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV . Her clinical work specializes in comprehensive HIV care for children through young adults, with particular focus on adolescent/young adult transition issues and global health initiatives through Lespwa Timoun in Haiti. Recent efforts include developing COVID-19 treatment guidelines for children and school safety protocols. HIV Specialist certification (American Academy of HIV Medicine) Fellow, Infectious Diseases Society of America Fellow, Pediatric Infectious Diseases Society Fellow, HIV Medical Association Member, HIV Medical Association's 'Ending the HIV Epidemic' working group She leads MUSC's HIV education initiatives and serves as inpatient consultant for pediatric infectious diseases, with advanced training in tropical medicine. Her NIH-funded research examines targeted interventions to minimize comorbidity development in HIV, while her clinical leadership spans the Ryan White HIV program, transition clinics, and global health partnerships.

• HIV-related cardiometabolic complications
• Antiretroviral therapy optimization
• Pediatric infectious diseases
• +7 more

Dr. Steven G. Clarke is a Distinguished Professor at UCLA Department of Chemistry & Biochemistry and director of research at the Molecular Biology Institute . His work bridges protein chemistry , methylation biology , and aging research through studies of spontaneous protein damage and its repair mechanisms. Education: BA in Chemistry and Zoology, Pomona College (magna cum laude, Phi Beta Kappa) PhD in Biochemistry and Molecular Biology, Harvard University (NSF Fellow) Postdoctoral Fellowship at UC Berkeley (Miller Fellow) Dr. Clarke's research focuses on protein isoaspartyl repair via PCMT1/PIMT enzymes , ribosomal protein methylation in Saccharomyces cerevisiae , and PRMT family characterization including PRMT7 and PRMT9. His lab combines biochemical assays , genetic models , and structural analysis to investigate aging mechanisms and disease implications. Recent publications highlight: COQ5 structure-function analysis in coenzyme Q biosynthesis PCMTD1 ubiquitin ligase interactions PRMT7 substrate specificity in histone H2B Protein isoaspartyl impacts on T cell function in lupus Novel PRMT inhibitors for cancer therapy Methionine addiction in osteosarcoma malignancy Major scientific awards: American Chemical Society Ralph F. Hirschmann Award in Peptide Chemistry NIH MERIT Award Ellison Medical Foundation Senior Scholar Award William C. Rose Award, ASBMB UCLA Distinguished Teaching Award (Eby Award winner) Current lab members include PhD candidates Eric Pang (UCSB) and Sining "Cindy" Wang (UCLA), while undergraduates Celeste Medina-Seymoure , Elizabeth Oroudjeva , Olivia Pacheco , and Jasmine Winter contribute to ongoing proteostasis studies. Collaborations with Profs. Jose Rodriguez and Catherine Clarke demonstrate interdisciplinary research approaches.

• Biochemistry
• Systems Biology
• Biological Regulation
• +8 more

Jonathan H. Cantor is a Policy Researcher and Professor of Policy Analysis at the RAND School of Public Policy . His research focuses on health policies related to substance use disorder , mental health , and health behaviors , integrating frameworks from health economics , policy analysis , and public health . He leads the Mental Health and Addiction Treatment Tracking Repository , a national longitudinal database for substance use and mental health treatment facilities. His work examines treatment availability for older adults (funded by the National Institute on Aging) and telehealth services in mental health (funded by the National Institute of Mental Health). Recent NIMH grants aim to quantify mental health crisis services supply and its impact on population health. His recent publications (e.g., JAMA , Health Affairs ) address topics like opioid treatment accessibility , telehealth disparities , and food insecurity in higher education . His research spans health equity , preventive healthcare , and modeling/simulation approaches.

• Substance Use Disorder
• Mental Health
• Health Behaviors
• +10 more

Aditi Das is a Full Professor in the School of Chemistry and Biochemistry at the Georgia Institute of Technology, College of Sciences. She leads the Das Laboratory, which focuses on the biochemistry and chemical biology of lipids, particularly studying cytochrome P450 enzymes and their role in lipid metabolism, endocannabinoid systems, and inflammatory pathways. Her educational background includes: B.Sc. in Chemistry from St. Stephen's College M.Sc. in Chemistry from Indian Institute of Technology, Kanpur (I.I.T) Ph.D. in Chemistry from Princeton University Postdoctoral research at Northwestern University (NSF-NSEC fellow) and Beckman Institute for Advanced Science and Technology, University of Illinois UC Professor Das's research interests center around understanding the physiological role of lipids in sustaining homeostasis and their implications in disease states such as neurodegenerative disorders, cancer, and cardiovascular diseases. Her laboratory specializes in: Enzymology of cytochrome P450s, particularly CYP2J2 epoxygenase Metabolism of ω-3 and ω-6 fatty acids and their derivatives Minor cannabinoid metabolism by cytochrome P450 enzymes Discovery of novel anti-inflammatory lipid metabolites and endocannabinoids Mechanistic studies of membrane proteins using nanodisc technology Her work bridges biochemistry, chemical biology, and pharmacology to uncover novel therapeutic targets related to lipid signaling pathways. Analysis of Professor Das's recent publications (2023-2025) reveals a strong focus on cannabinoid metabolism by cytochrome P450 enzymes, with particular emphasis on how these metabolic processes generate bioactive compounds that interact with the endocannabinoid system. Her research increasingly explores the therapeutic potential of omega-3 derived endocannabinoid epoxides in inflammatory and neurodegenerative conditions. The use of nanodisc technology for studying membrane proteins in near-native environments remains a consistent methodological thread throughout her work, enabling detailed mechanistic insights into enzyme function. Professor Das has received numerous prestigious awards recognizing her research excellence and teaching: 2024 NIH Outstanding Researcher Award (MIRA R35) for established investigators 2024 Vasser Woolley Faculty Fellowship 2023 Plenary Lecture at the International Society of the Study of Xenobiotics (ISSX) 2021 E.L.R. Stokstad Award 2019-2021 List of Teachers Ranked as Excellent 2019 Eicosanoid Research Foundation Young Investigator Award 2019 Zoetis Research Excellence Award 2019 Mary Swartz Rose Young Investigator Award 2015 National Scientist Development Award from the American Heart Association 2022 El Sohly Award from the American Chemical Society Professor Das actively mentors a diverse group of students and postdoctoral researchers, with several former lab members now holding faculty positions or working at prestigious institutions. Her laboratory has secured significant funding from NIH, NSF, and other sources to support research on lipid metabolism, cannabinoid pharmacology, and membrane protein biochemistry. Notable grants include an NIH R35 Outstanding Investigator Award (MIRA), an NIH R21 grant from NIDA, and multiple collaborative grants with other research groups. The Das Laboratory operates within the Petit Institute of Bioengineering and Biosciences (IBB) at Georgia Tech, utilizing state-of-the-art facilities for biochemical and biophysical studies. The lab specializes in nanodisc technology to study membrane proteins in near-native environments, with particular expertise in cytochrome P450 enzymes and their interactions with lipid substrates. Recent work has expanded into collaborative projects involving lipidomics, structural biology, and translational applications of lipid signaling research.

• Biochemistry and Chemical biology of Lipids
• Mechanism of Membrane proteins in Nanodiscs
• Enzymology of metalloproteins
• +5 more

Benjamin Andrew Toll is a Professor in the Department of Public Health Sciences and Psychiatry at the Medical University of South Carolina (MUSC) College of Medicine. He serves as Associate Director of Education and Training for the Hollings Cancer Center, Vice Chair of Research in the Department of Public Health Sciences, Co-Director of the Lung Cancer Screening Program, and Director of the Tobacco Treatment Program at MUSC. Dr. Toll received his BA from Cornell University (1996), MS and PhD from Nova Southeastern University (1999, 2002), and completed his Postdoctoral Fellowship and Internship at Yale University. Dr. Toll is a leading researcher in tobacco cessation, with over 20 years of experience conducting clinical trials focused on developing novel therapeutics for tobacco and nicotine use. His work primarily centers on preventing cancer through tobacco treatment interventions, with particular emphasis on lung cancer screening patients and cancer surgery patients. He has expertise in nicotine replacement therapy, contingency management approaches, gain-framed messaging, and digital health interventions for smoking cessation across diverse populations including older adults and young adults. His recent publications demonstrate a strong focus on implementation science for tobacco treatment programs across various healthcare settings including hospitals, oncology clinics, and primary care. His research examines barriers to treatment, optimal delivery methods (including telehealth and EHR-integrated tools), and effectiveness of various pharmacological and behavioral interventions for smoking cessation. National Cancer Institute funding (R01CA235697, R01CA207229, P50CA196530) National Institute on Drug Abuse funding (P50DA036151, K12DA000167) Continuous funding for over 15 years for tobacco cessation research As a mentor and leader, Dr. Toll oversees the Education and Training program at the Hollings Cancer Center, guiding the development of future cancer researchers. His Tobacco Treatment Program serves as a model for integrating tobacco cessation into comprehensive cancer care, and he has successfully implemented 'opt-out' tobacco treatment programs across multiple hospital systems in South Carolina. Dr. Toll leads a multidisciplinary research team focused on tobacco treatment, including psychologists, pharmacists, physicians, and implementation scientists working together to develop and test innovative approaches to smoking cessation for high-risk populations.

• Tobacco Cessation
• Smoking Cessation
• Cancer Prevention
• +5 more

Eileen Klein is an Associate Professor of Social Work and Convener of the BSW Program at Ramapo College of New Jersey's School of Social Science and Human Services. Her work focuses on LGBTQ mental health treatment , community support systems , and policy reform for marginalized populations. Klein has presented extensively at international conferences on topics like cultural competency in social work education and LGBTQ health disparities . Ph.D., M.S., and M.S.W. from New York University and SUNY Buffalo Key research areas: LGBTQ Mental Health, Community Health Disparities, Forensic Social Work Published 15+ works (2013-2021) on topics ranging from polypharmacy to support programs for LGBTQ clients Active in professional development: Delivered presentations at conferences across the U.S. and Italy on topics including integrated treatment and supervision of student interns

• Community Mental Health
• LGBTQ Mental Health Treatment
• Social Work Policy Advocacy
• +3 more

Jennifer D. Oliva is a Professor of Law at Indiana University Maurer School of Law where she holds the Val Nolan Faculty Fellow position. She maintains significant interdisciplinary affiliations as a Research Scholar at Georgetown University Law Center's O'Neill Institute for National & Global Health Law and as a Senior Scholar with the UCSF/UC Law Consortium on Law, Science & Health Policy. Her academic work bridges legal scholarship with practical health policy development, focusing on the intersection of constitutional protections, public health needs, and modern surveillance technologies. Professor Oliva's research interests center on health law, privacy law, and drug policy with particular expertise in prescription drug monitoring programs (PDMPs), health information privacy, and the legal dimensions of the opioid crisis. Her scholarship critically examines how law enforcement surveillance of prescription data impacts patient privacy rights, particularly for vulnerable populations including those with substance use disorders. She has developed significant expertise in how constitutional privacy protections apply to health data in the digital age, especially following the Supreme Court's decision in Carpenter v. United States. Her recent publications reveal a growing focus on algorithmic regulation in healthcare, examining how risk scoring systems and coverage algorithms can perpetuate health disparities. She has published extensively on the intersection of reproductive rights and health data privacy in the post-Dobbs landscape, analyzing how prescription monitoring systems could be weaponized against individuals seeking reproductive healthcare. Her work consistently connects doctrinal legal analysis with public health realities, advocating for evidence-based policy approaches that prioritize patient privacy and health equity over punitive enforcement. Dosing Discrimination: Regulating PDMP Risk Scores (2022) The "New" Drug War (2024) Prescription Drug Policing: The Right to Health Information Privacy Pre- and Post-Carpenter (2020) Opioid Multidistrict Litigation Secrecy (2019) Surveillance, Privacy, and App Tracking (2020) Professor Oliva actively engages with policymakers and has contributed to amicus briefs in significant cases including Ruan v. United States. Her scholarship has been cited in legal proceedings and she regularly presents at major academic conferences including the Association of American Law Schools Annual Meeting. She has collaborated with scholars across disciplines including public health researchers, medical ethicists, and data scientists to address complex challenges at the intersection of law, technology, and healthcare.

• Health Law
• Privacy Law
• Drug Policy
• +7 more

Deepak Ganesan is a Professor at the Manning College of Information and Computer Sciences (CICS) at the University of Massachusetts Amherst. His research focuses on low-power sensing and communication, networked systems, and machine learning applied to pervasive health monitoring and societal challenges. PhD, Computer Science, University of California, Los Angeles (2004) MS, Computer Science, University of California, Los Angeles (2000) BTech, Computer Science, Indian Institute of Technology, Madras (1998) Ganesan's work bridges wireless sensor networks, smart textiles, and healthcare applications. He designs ultra-low-power wearable devices for tracking health signals like drug use, smoking, and cognitive performance, often integrating machine learning for robust detection. His research emphasizes societal impact, particularly in aging and Alzheimer's care through the Massachusetts AI and Technology Center for Connected Care (MassAITC) and the Center for Personalized Health Monitoring (CPHM). Recent publications highlight innovations in edge-cloud collaboration, fabric-based sensors, and longitudinal health analytics. His NIH-funded MD2K Center for Excellence and affiliations with the Center for Data Science and Computational Social Science Institute further underscore his interdisciplinary approach. ACM Fellow NSF CAREER Award (2006) IBM Faculty Award (2008) UMass Junior Faculty Fellow (2008) UMass Lilly Teaching Fellow (2009) Best Paper at CHI 2013 Best Paper Runner-up at Mobicom 2014 Honorable Mentions at Ubicomp 2013 Ganesan leads the SENSORS: Wireless Sensor Networks Group and contributes to global initiatives like the Internet of Battlefield Things. His work spans academic research, industry partnerships, and policy development in AgeTech and digital health.

• Networking and Distributed Systems
• Mobile and Sensor Systems
• Human-Computer Interactions
• +3 more

Samantha J. Harris, PhD, MPA, is an Assistant Scientist in the Department of Health Policy and Management at the Johns Hopkins Bloomberg School of Public Health. Her primary appointment is with the Bloomberg Overdose Prevention Initiative, where she leads state-level evaluations in Kentucky and New Mexico, focusing on overdose prevention and implementation of harm reduction policies. Institution: Johns Hopkins University School: Bloomberg School of Public Health Department: Department of Health Policy and Management Position: Assistant Scientist Education: PhD in Health Policy, University of Georgia, 2021 MPA in Health Policy, University of Kentucky, 2016 BA in Arts Administration, University of Kentucky, 2014 Postdoctoral Training, Johns Hopkins Bloomberg School of Public Health Samantha Harris's research centers on improving access to mental health and substance use treatment, particularly through public insurance programs like Medicaid and Medicare. Her work applies mixed-methods approaches to evaluate policies related to harm reduction, overdose prevention, and service delivery within the criminal legal system. She has a strong interest in aging and health, opioid and alcohol use disorders, and equitable access to care. Her recent publications highlight trends in Medicare coverage for methadone and buprenorphine, implementation of syringe services programs, and attitudes toward decriminalization policies. Her work spans qualitative and quantitative methods, often focusing on policy impact and implementation barriers at the state level. Scientific Contributions: Lead researcher on rapid-cycle evaluations of overdose prevention programs Co-Investigator on NIH, SAMHSA, and privately funded projects Frequent collaborator with interdisciplinary teams and state agencies Harris has served in policy-focused fellowship placements and contributes to high-impact journals such as Health Affairs and Drug and Alcohol Dependence . She advises on policy evaluation and health services research but no formal students are listed. She is actively involved in the Bloomberg Overdose Prevention Initiative, working closely with Dr. Brendan Saloner and Dr. Sachini Bandara. Her lab or team is embedded within this initiative, conducting real-time assessments of innovative state policies to reduce fatal overdoses.

• Health Policy
• Health Services Research
• Substance Use Treatment
• +8 more

Dr. Rodolfo J. Flores serves as an Assistant Professor in the Department of Psychology within the College of Liberal Arts at the University of Texas at El Paso (UTEP). His primary research investigates neuromodulator function in the prefrontal cortex, with emphasis on acetylcholine and dynorphin systems during motivational conflict, stress responses, and addiction pathways. He employs advanced optogenetic and biosensor technologies to dissect neural circuitry underlying psychiatric conditions. Dr. Flores earned his Ph.D. in Social Cognitive and Neuroscience from UTEP in 2019, followed by postdoctoral training at the National Institute of Mental Health (NIMH). His work bridges molecular neuroscience with behavioral outcomes, focusing on how stress and substance exposure alter prefrontal cortical function. His research portfolio demonstrates consistent high-impact publication in top neuroscience journals including Nature Neuroscience , Neuron , and Psychoneuroendocrinology . Current work examines opioid neuropeptide dynamics, nicotine-alcohol interactions, and sex-specific hormonal influences on addiction behaviors. Methodologically, he specializes in genetically encoded biosensors and circuit-level manipulations to study threat processing and reward pathways. Dr. Flores teaches graduate and undergraduate courses including PSYC 4341 (Motivation & Emotion), thesis/dissertation supervision (PSYC 5395/6395), and research applications courses. His lab actively trains students through undergraduate research (RSRC 4033) and independent study opportunities (PSYC 4352).

• Behavioral Neuroscience
• Neuromodulators
• Prefrontal Cortex Function
• +3 more

Angela Birnbaum is a Professor in the Department of Experimental and Clinical Pharmacology at the University of Minnesota College of Pharmacy. She serves as Associate Director of the Center for Clinical and Cognitive Neuropharmacology and is a Fellow of The American Epilepsy Society (FAES). Her research focuses on translational clinical pharmacology with emphasis on special populations including the elderly, pregnant women, children, and those with drug addiction. Dr. Birnbaum earned her PhD in Pharmacology (with a Neuroscience minor) from the University of Minnesota Department of Pharmacology. She completed her undergraduate studies with a Bachelor of Science and Medical Technology (BSMT) with chemistry minor from Ohio Northern University, along with a Bachelor of Biology (BS). She also completed a Medical Technology Internship at St. Rita's Medical Center and a Post-doctoral Fellowship in Clinical Neuropharmacology at the University of Minnesota. Her research program centers on pharmacokinetics and pharmacodynamics in special populations, with particular expertise in antiepileptic drugs. She investigates drug concentration variability and response across different patient groups, with significant work on medications like lamotrigine, carbamazepine, and lacosamide. Her laboratory operates as a Pharmacokinetics Laboratory Core for various grant projects and explores drug stability both in vivo and in vitro. Dr. Birnbaum's recent publications demonstrate a strong focus on pregnancy-related pharmacokinetics, particularly for antiepileptic medications, and pharmacokinetic considerations for vulnerable populations including neonates and critically ill patients. Her work combines pharmacometric modeling with clinical research to optimize drug dosing across diverse patient populations. Among her notable recognitions: Fellow of The American Epilepsy Society (FAES) Designation as Center of Excellence for Model-based Drug Development (MBDD) Certara Center of Excellence designation for her program Dr. Birnbaum has been principal investigator and collaborator on numerous research projects funded by the National Institutes of Health, pharmaceutical industry, instrumentation companies, and foundations. Her current projects include investigations into antiseizure medication exposure during pregnancy and breastfeeding, development of monoclonal antibodies to reverse fentanyl overdose, and clinical trials of multivalent opioid vaccine components. Her laboratory, the Birnbaum Laboratory for Translational Clinical Neuropharmacology, operates as both an independent research program investigating drug effects on cognition and a Pharmacokinetics Laboratory Core supporting multiple research projects. The lab incorporates Certara's Phoenix software suite into thesis and research projects, reflecting their expertise in model-based drug development.

• Pharmacokinetics
• Clinical Pharmacology
• Neuropharmacology
• +7 more

Matthew W. Buczynski is an Assistant Professor at the School of Neuroscience , part of the College of Science at Virginia Tech . Holding a Ph.D. in Biochemistry from the University of California San Diego (2008) and postdoctoral training at The Scripps Research Institute (2009-2016), he joined Virginia Tech in August 2016 after completing his postdoctoral fellowship. Education: B.S. in Chemistry, University of Michigan , 2001 Ph.D. in Biochemistry, University of California San Diego , 2008 Postdoctoral Training, The Scripps Research Institute , 2009-2016 Dr. Buczynski’s research program focuses on identifying novel druggable targets for addiction and neurological disorders through mass spectrometry and behavioral pharmacology . His work integrates chemical biology , molecular pharmacology , and in vivo microdialysis to study molecular changes in the brain during chronic drug exposure. Key areas include nicotine dependence , ethanol withdrawal , and cross-talk between pain and addiction mechanisms. His recent publications highlight endocannabinoid system modulation , TRPV1/TRPA1 receptor activation in pain, and diacylglycerol lipase (DAGL) mechanisms in nicotine withdrawal. He employs both self-administration and forced exposure models to validate therapeutic targets. Prospective students can contact him directly through his lab’s website .

• Neuroscience
• Drug Addiction
• Pharmacology
• +3 more

Affiliations & Roles Professor of Computer and Information Science at University of Pennsylvania Faculty in Graduate Groups: Bioengineering (School of Engineering) Genomics & Computational Biology (School of Medicine) Operations, Information & Decisions (Wharton School) Psychology (School of Arts & Sciences) Research Affiliations: Annenberg Public Policy Center (Distinguished Fellow) Center for Cognitive Neuroscience Institute for Translational Medicine Research Interests Focuses on explainable AI, natural language processing (NLP), and machine learning applications in psychology and medicine. Key areas include: Language analysis for well-being and mental health Spectral methods for NLP (e.g., Eigenwords) Forecasting and decision-making models Bioinformatics and genomics Teaching Teaches advanced courses in Machine Learning, Deep Learning, and AI ethics, including: CIS 5200: Machine Learning CIS 5220: Deep Learning CIS 6200: Advanced Topics in Deep Learning Key Collaborations Works with interdisciplinary teams on projects like the Good Judgment Project (forecasting) and WWBP (Well-Being and Language). Collaborators include Martin Seligman (positive psychology), Dean Foster (statistics), and Michael Collins (NLP).

• Artificial Intelligence
• Machine Learning
• Natural Language Processing
• +7 more

Dr. Douglas Lobner is a Research Professor in the Department of Biomedical Sciences at Marquette University, College of Health Sciences. His research focuses on neurodegenerative disease mechanisms, environmental toxin interactions, and dental material toxicity. He investigates how environmental factors like mercury, pesticides, and BMAA interact with genetic predispositions to cause neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and ALS, particularly through the cystine/glutamate transporter (system xc-). His work also explores dental pulp capping materials, emphasizing growth factor-enhanced repair mechanisms and system xc- regulation to prevent root canal procedures. Key collaborations involve studies on glutamate signaling, neurotoxicant synergy, and drug-induced neuroplasticity. Published research includes over 14 studies from 2009–2014, emphasizing system xc- regulation by growth factors, neurotoxin synergies (e.g., methylmercury and BMAA), and dental material toxicity mitigation strategies. His lab contributes to the Neuroscience Collaboratory and Integrative Neuroscience Research Center at Marquette.

• Neurodegenerative Diseases
• Environmental Toxicology
• Neurotoxicology
• +4 more

Patrick Skeba is a Teaching Assistant Professor at the University of Pittsburgh's Department of Computer Science within the School of Computing and Information. He holds a PhD in Computer Science from Lehigh University (2022) and bachelor's degrees in Cognitive Science and Computer Science from Johns Hopkins University (2017). His research focuses on internet privacy, AI ethics, and the responsible use of data. He teaches courses in machine learning and programming. Research Interests: Skeba's work bridges technology and societal impact, emphasizing privacy risks in data systems, algorithmic fairness, and user-centric privacy frameworks. His recent studies explore informational friction in data collection, community-based privacy strategies, and lay-expert disparities in understanding privacy-enhancing technologies (PETs). Publications: His articles analyze privacy dynamics in digital spaces, from pandemic-era discourse on r/privacy to methodological approaches for categorizing technology non-use. His earlier work includes breakthroughs in sleep disorder diagnostics, particularly periodic leg movement (PLM) analysis and telemedicine applications for neurological conditions. Awards: No scientific awards listed. Grants and advising details are currently unspecified. Labs/Teams: No specific lab affiliations mentioned in provided materials. His teaching and research emphasize collaboration across computational and social domains.

• Internet Privacy
• Artificial Intelligence
• Data Ethics
• +3 more